Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Tarsus Pharmaceuticals stock | $37.16

Learn how to easily invest in Tarsus Pharmaceuticals stock.

Tarsus Pharmaceuticals, Inc
-$0.20 (-0.88%)

Tarsus Pharmaceuticals, Inc is a biotechnology business based in the US. Tarsus Pharmaceuticals shares (TARS) are listed on the NASDAQ and all prices are listed in US Dollars. Tarsus Pharmaceuticals employs 20 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Tarsus Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – TARS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Tarsus Pharmaceuticals stock price (NASDAQ: TARS)

Use our graph to track the performance of TARS stocks over time.

Tarsus Pharmaceuticals shares at a glance

Information last updated 2021-07-28.
Latest market close$37.16
52-week range$15.33 - $63.69
50-day moving average $29.82
200-day moving average $32.75
Wall St. target price$51.20
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Tarsus Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stocks, Options, ETFs
$0 per year
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Tarsus Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Tarsus Pharmaceuticals price performance over time

Historical closes compared with the close of $37.16 from 2021-06-08

1 week (2021-07-22) N/A
1 month (2021-07-02) 29.75%
3 months (2021-04-30) 20.96%
6 months (2021-01-29) N/A
1 year (2020-07-29) N/A
2 years (2019-07-29) N/A
3 years (2018-07-29) N/A
5 years (2016-07-29) N/A

Tarsus Pharmaceuticals financials

Revenue TTM $33.4 million
Gross profit TTM $0
Return on assets TTM -7.08%
Return on equity TTM -12.03%
Profit margin -43.31%
Book value $8.93
Market capitalisation $486 million

TTM: trailing 12 months

Shorting Tarsus Pharmaceuticals shares

There are currently 327,185 Tarsus Pharmaceuticals shares held short by investors – that's known as Tarsus Pharmaceuticals's "short interest". This figure is 3% up from 317,509 last month.

There are a few different ways that this level of interest in shorting Tarsus Pharmaceuticals shares can be evaluated.

Tarsus Pharmaceuticals's "short interest ratio" (SIR)

Tarsus Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Tarsus Pharmaceuticals shares currently shorted divided by the average quantity of Tarsus Pharmaceuticals shares traded daily (recently around 97087.537091988). Tarsus Pharmaceuticals's SIR currently stands at 3.37. In other words for every 100,000 Tarsus Pharmaceuticals shares traded daily on the market, roughly 3370 shares are currently held short.

To gain some more context, you can compare Tarsus Pharmaceuticals's short interest ratio against those of similar companies.

However Tarsus Pharmaceuticals's short interest can also be evaluated against the total number of Tarsus Pharmaceuticals shares, or, against the total number of tradable Tarsus Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Tarsus Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Tarsus Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0712% of the tradable shares (for every 100,000 tradable Tarsus Pharmaceuticals shares, roughly 71 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Tarsus Pharmaceuticals.

Find out more about how you can short Tarsus Pharmaceuticals stock.

Tarsus Pharmaceuticals share dividends

We're not expecting Tarsus Pharmaceuticals to pay a dividend over the next 12 months.

Tarsus Pharmaceuticals overview

Tarsus Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. .

Frequently asked questions

What percentage of Tarsus Pharmaceuticals is owned by insiders or institutions?
Currently 28.651% of Tarsus Pharmaceuticals shares are held by insiders and 62.438% by institutions.
How many people work for Tarsus Pharmaceuticals?
Latest data suggests 20 work at Tarsus Pharmaceuticals.
When does the fiscal year end for Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals's fiscal year ends in December.
Where is Tarsus Pharmaceuticals based?
Tarsus Pharmaceuticals's address is: 15440 Laguna Canyon Road, Irvine, CA, United States, 92618
What is Tarsus Pharmaceuticals's ISIN number?
Tarsus Pharmaceuticals's international securities identification number is: US87650L1035

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site